ClinicalTrials.gg
RecruitingNCT07682831Updated Aug 19, 2026

Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies

An interventional study of Two photon microscopy imaging in Basal Cell Carcinoma of Skin and Squamous Cell Carcinoma (Skin), sponsored by University of Rochester. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by University of Rochester · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Planned enrollment
39th of 139
92 · median 40
Started
2026
with 9 others
No phase
37 of 171
6 open now
Primary completion
2027-06
later than 19 of 37 live
Registered
170th of 171
by date

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 39th largest by planned enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2026, is one of 37 with no phase, reaches primary completion later than 19 of the 37 other live ones, and was the 170th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to investigate the ability of a machine learning model to evaluate two-photon fluorescence microscopy images of dermatologic biopsies at point of care.

The main question it aims to answer is:

  • How well do two-photon fluorescence images of biopsies taken in a clinic and evaluated by a machine learning model agree with conventional histology?
Read the detailed description

This study will image biopsy specimens at point of care using two-photon fluorescence microscopy (TPFM) and then assess how well the images predict the eventual clinical diagnosis using a machine learning model. Because two-photon images can be acquired from small biopsy specimens within minutes of excision, they could potentially be used to immediately diagnose patients, but the accuracy of TPFM for various skin conditions is unknown.

Individual biopsy specimens in a dermatology clinic will be imaged using TPFM shortly after biopsy procedures. Immediately following imaging, a machine learning model will evaluate the TPFM images then compute a confidence score for a diagnosis of basal cell carcinoma (BCC), squamous cell carcinoma, and non-cancer. The relative confidence in each diagnosis will be compared, and if sufficient confidence is achieved, the model will render a diagnosis or else flag the specimen as indeterminate for manual pathologist review. This workflow will evaluate the use of ML + TPFM to perform point of care diagnosis of skin lesions.

Following TPFM imaging, the specimen will be submitted for histological processing, which will guide actual patient treatment. Following conclusion of patient treatment, the resulting histology slides will be scanned for comparison and the final patient diagnosis recorded. Images of the histology slides will be read by a pathologist to establish a gold-standard diagnosis. The official diagnosis and the diagnosis from the collaborating pathologist will be compared.

Patient treatment will still be decided by conventional histopathology. TPFM will not be used to change treatment.

03

Conditions studied

  • Basal Cell Carcinoma of Skin
  • Squamous Cell Carcinoma (Skin)

Keywords

  • two-photon microscopy
  • machine learning
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Punch, excisional or shave specimen

Exclusion criteria

Exclusion Criteria:

  • indication includes melanoma or dysplastic/atypical nevus
  • Excision thickness of less than 1 mm
  • Excision longest dimension less than 2 mm
  • Excision performed as multiple pieces in a single specimen container
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    TPFM imaging of biopsy

    Specimens will be imaged with TPFM and diagnosed using a machine learning model

    Device: Two photon microscopy imaging

Interventions

  • DeviceTwo photon microscopy imaging

    Ex vivo tissues will be imaged with two-photon microscopy and analyzed with machine learning for diagnosis

06

What researchers measure

Primary outcomes

  1. Sensitivity of Machine Learning Analysis of Two Photon Fluorescence Microscopy Images At Point of Care

    A machine learning model will evaluate TPFM images of patient biopsies at point of care. Sensitivity will be calculated for the machine learning model using two photon fluorescence microscopy images. Sensitivity is defined as the number of true positive diagnoses divided by the sum of true positive and false negative diagnoses among biopsy specimens for which the machine learning model provides a definitive diagnosis. The patient's ultimate clinical diagnosis will serve as the reference standard.

    Time frame: During or immediately following patient biopsy (same day)

  2. Specificity of Machine Learning Analysis of Two Photon Fluorescence Microscopy Images At Point of Care

    A machine learning model will evaluate TPFM images of patient biopsies at point of care. Specificity will be calculated for the machine learning model using two photon fluorescence microscopy images. Specificity is defined as the number of true negative diagnoses divided by the sum of true negative and false positive diagnoses among biopsy specimens for which the machine learning model provides a definitive diagnosis. The patient's ultimate clinical diagnosis will serve as the reference standard.

    Time frame: During or immediately following patient biopsy (same day)

Secondary outcomes

  1. Proportion of Discordant Diagnoses Attributable to Machine Learning Model Interpretation Errors

    For biopsy specimens with discordant diagnoses between the machine learning model and the patient's ultimate clinical diagnosis, a dermatopathologist will review each case and classify the source of disagreement as machine learning model interpretation error, image quality limitation, or image coregistration error. The proportion of discordant diagnoses attributable to each source of disagreement will be reported.

    Time frame: After completion of patient diagnosis (typically 1-2 weeks after procedure)

  2. Proportion of Biopsy Specimens With a Definitive Machine Learning Diagnosis

    The proportion of biopsy specimens for which the machine learning model provides a definitive diagnosis based on two photon fluorescence microscopy images will be calculated as the number of specimens receiving a definitive diagnosis divided by the total number of specimens evaluated.

    Time frame: During or immediately following patient biopsy (same day)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified sets of two-photon images and corresponding conventional histology will be made available upon request. Links to full resolution image data will be included in publications along with the results of machine learning analysis.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 50 interventional studies with no phase under Carcinoma, Basal Cell, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 64. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 6, 2026
StartActual
Jun 24, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07682831
Collaborators
National Cancer Institute (NCI), Rochester Dermatologic Surgery
Responsible party
Michael Giacomelli (Associate Professor, University of Rochester) — Principal investigator
First posted
Jul 6, 2026
Start date
Jun 24, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Michael Giacomelli, Ph.D
Contact
mgiacome@ur.rochester.edu
5852766260

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion